Current status of Parkinson's disease treatment in Korea

Abstract

The health insurance system in Korea has been under governmental control, and has covered whole population since 1989. About 97% of Korean people have benefits from this system, while 3% are covered by a Medical Aid system for poor people. According to the statistical yearbook of Health Insurance Review in Korea, the number of claims under Parkinson's Disease, in whole country increased steeply from 44619 in 1995 to 96229 in 2000. If each patient were to take medication for the full duration of their insurance coverage, the average number of visits per year would be 11 in 2000. Thus the number of PD patients calculated using these statistics is about 8600. The prevalence is 19/100000, which is much lower than that in Japan. Considering the significant increase in the number of claims in last few years, however, there are still many PD patients who do not receive an accurate diagnosis and appropriate treatment. The other factor influencing these statistics is the fact that patients were able to buy their medications in drug stores without prescription, i.e. without visiting a hospital (since 2001 this has no longer been allowed). Almost all PD medications are available in Korea. There are several forms of levodopa drugs. Dopamine agonists include bromocriptine, pergolide, dihydroergocriptine, ropinirol, and pramipexole. Other parkinsonian medications are amantadine, benztropin, trihexyphenydil, deprenyl, and entacapone. Recently multicentre clinical trials were performed using ropinirol and entacapone, which showed reliable results. Currently deep brain stimulation is available in a number of medical institutes.